A research team at the Icahn School of Medicine at Mount Sinai has achieved a major structural biology breakthrough by identifying a previously hidden, druggable binding site on PKMYT1, a critical kinase protein that regulates how tumor cells grow and divide. Published in the Journal of the American Chemical Society, the discovery is drawing immense interest from the scientific community because this specific binding pocket was completely missed by state-of-the-art artificial intelligence protein prediction models and previous computational screening frameworks. Traditionally, experimental oncology drugs targeting kinase proteins have focused almost exclusively on blocking the highly conventional ATP-binding site—the specific region the cell uses to draw energy—but these often suffer from severe toxicity issues and a lack of molecular specificity. By utilizing an innovative combination of AlphaFold2 simulations paired with intensive local laboratory validation, the researchers proved that PKMYT1 is far more flexible and dynamic than previously believed, constantly morphing between entirely unexpected structural shapes. The study revealed a highly sensitive molecular mechanism wherein a remarkably tiny chemical modification could cause a therapeutic molecule to switch its binding behavior entirely, shifting from the newly uncovered hidden pocket back to a conventional, less effective site. Leading pharmacologists note that targeting this highly unique, newly discovered pocket provides an unprecedented pathway to engineer next-generation, hyper-selective cancer therapies that can systematically eliminate tumor cells while safely sparing healthy surrounding tissue. Furthermore, the empirical data generated from this project is expected to be funneled back into machine learning pipelines, effectively teaching future AI drug discovery algorithms how to accurately predict these hidden, highly dynamic protein states without relying solely on physical trial-and-error. Moving forward, the Mount Sinai team plans to optimize these compounds in disease models and investigate whether identical hidden pockets exist across other complex, treatment-resistant cancer kinases.